Minimal Residual Disease Monitoring By Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM) in Patients with Multiple Myeloma Receiving Ciltacabtagene Autoleucel

Key Points

• Monitoring minimal residual disease using serum m-protein tracking is vital for patient management in multiple myeloma.
• The study highlights the significant role of mass spectrometry in accurately tracking disease progression with high sensitivity.
• Targeted analysis revealed that patients receiving ciltacabtagene autoleucel showed improved disease monitoring outcomes.
• Effective tracking methods may enable personalized treatment strategies and optimize patient care for those with multiple myeloma.